RxDoctor Payments DataLook up a doctor →

Paul Peterson, DO

Family Medicine · Sioux City, IANPI 1326013426

Payments from drug & device makers

$7,683in general payments, 2019–2025

Across 537 payments — averaging $14.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • AstraZeneca$1K
  • Novo Nordisk$782
  • Pfizer$686
  • AbbVie$369
  • Astellas Pharma US Inc$342
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$7,658100%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,683 in reported general payments places this provider in the 95th percentile of 1,357 family medicine providers in Iowa.

See all family medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$271,717
Medicare patients
325
Services billed
12,899

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide109$109,017
EliquisApixaban92$76,287
FarxigaDapagliflozin Propanediol52$30,829
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$27,968
Tresiba Flextouch U-200Insulin Degludec19$25,004
JanuviaSitagliptin Phosphate34$20,157
MyrbetriqMirabegron32$16,006
Breo ElliptaFluticasone/Vilanterol32$15,699
JardianceEmpagliflozin12$15,109
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog25$14,833
XareltoRivaroxaban24$14,679
Atorvastatin Calcium507$5,739
Modafinil19$5,508
Novolog FlexpenInsulin Aspart15$4,993
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$4,614

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$782$109,017109 claims
PfizerEliquis$686$76,28792 claims
GSKTrelegy Ellipta, Breo Ellipta$207$43,66770 claims
AstraZenecaFarxiga$1,007$30,82952 claims
MerckJanuvia$314$20,15734 claims
Astellas Pharma US IncMyrbetriq$342$16,00632 claims
Boehringer IngelheimJardiance$175$15,10912 claims
Johnson & JohnsonXarelto$97$14,67924 claims
AbbVieSynthroid$369$1,78920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,357 family medicine providers in Iowa.

Other family medicine in Sioux City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →